Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab

Cancer Imaging

Volumn 12, Issue 1, 2012, Pages 225-236

  Nishino, Mizuki ^a   Cryer, Sarah K ^a   Okajima, Yuka ^a   Sholl, Lynette M ^a   Hatabu, Hiroto ^a   Rabin, Michael S ^a   Jackman, David M ^a   Johnson, Bruce E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiangiogenic therapy; Bevacizumab; Computed tomography; Non small cell lung cancer; Tumor cavitation

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL; PEMETREXED;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; HYPERTENSION; IMAGE ANALYSIS; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CAVITATION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PROTEINURIA; RASH; SMOKING; THORAX RADIOGRAPHY; TUMOR VOLUME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863594955     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2012.0027     Document Type: Article

References (19)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236. doi:10.3322/caac.20121.
2. American Cancer Society: Cancer facts and figures. 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-029771.pdf.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364. doi:10.1016/S0092-8674(00) 80108-7. (Pubitemid 26272076)
5. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86: 558-563. doi:10.1038/sj.bjc.6600130. (Pubitemid 34185092)
6. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3: 861-865. (Pubitemid 27252933)
7. Imoto H, Osaki T, Taga S, et al. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998; 115: 1007-1014. doi:10.1016/S0022-5223(98)70398-8. (Pubitemid 28224393)
8. Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 2009; 15: 5040-5048. doi:10.1158/1078-0432.CCR-09-0520.
9. Sandler A, Gray R, Perry MC, et al. Paclitaxelcarboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. doi:10.1056/NEJMoa061884. (Pubitemid 44917502)
10. Marom EM, Martinez CH, Truong MT, et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008; 3: 351-357. doi:10.1097/JTO.0b013e318168c7e9. (Pubitemid 351489474)
11. Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in nonsmall-cell lung cancer. J Clin Oncol 2009; 27: 404-410. doi:10.1200/JCO.2008. 16.2545.
12. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009; 27: 1405-1412. doi:10.1200/JCO.2008.16.2412.
13. National Comprehensive Cancer Network, Inc. The NCCN non-small cell lung cancer clinical practice guidelines in oncology (version 3.2011). 2011. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf.
14. Wilson AG, Hansel DM. Immunologic diseases of the lung. In: Armstrong P, Wilson AG, Dee P, Hansell DM, editors. Imaging of the diseases of the chest. 3rd ed. London: Mosby; 2000, p. 533-636.
15. Lee HY, Lee KS, Ahn MJ, et al. New CT response criteria in nonsmall cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer 2011; 73: 63-69. doi:10.1016/j.lungcan.2010.10.019.
16. Choi H, Charnsangavej C, Faria SC, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG-PET findings. AJR Am J Roentgenol 2004; 183: 1619-1628. (Pubitemid 44210530)
17. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759. doi:10.1200/JCO.2006.07.3049. (Pubitemid 46797957)
18. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrastenhanced CT. AJR Am J Roentgenol 2010; 194: 157-165. doi:10.2214/AJR.09.2941.
19. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010; 194: 1470-1478. doi:10.2214/AJR.09.3456.